What the $1b Roche-PathAI Deal Can Tell Clinical Lab Directors
Roche acquires a workflow rather than a company, says AI industry observer
Roche acquires a workflow rather than a company, says AI industry observer
From – Diagnostic Testing & Emerging Technologies
Nonsevere fetal malformations and structural abnormalities are relatively frequent findings of routine, prenatal ultrasounds. Yet, these findings provide…
From – Diagnostic Testing & Emerging Technologies
Despite the commonly held belief that the food allergy prevalence is rising, food allergies remain poorly studied and…
From – Diagnostic Testing & Emerging Technologies
Child–parent hypercholesterolemia (FH) screening is a practical and effective way of conducting population-based screening to identify the…
From – Diagnostic Testing & Emerging Technologies
With Theranos’ recent announcement of its transition away from laboratory operations toward technology development…
From – Diagnostic Testing & Emerging Technologies
Reanalysis of clinical exome data at a two- to three-year interval could result in an incremental 10 percent diagnostic yield…
From – Diagnostic Testing & Emerging Technologies
Patients increasingly prefer to receive laboratory test results via password-protected websites and portals, according to…